![Matthew Hirsch](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Ursprung des Netzwerks ersten Grades von Matthew Hirsch
Einheit | Art der Einheit | Industrie | |
---|---|---|---|
RainBio, Inc.
![]() RainBio, Inc. BiotechnologyHealth Technology Part of CalciMedica, Inc., RainBio, Inc. is a gene therapy company based in Raleigh, NC. RainBio, Inc. focuses on developing novel, sight-saving treatments for blinding corneal diseases. RainBio's lead program, RBIO-1, targets corneal blindness in mucopolysaccharidosis I (MPS I), a rare genetic disorder in children. Gary Jay Sternberg has been the CEO of the company since October 12, 2021. RainBio was acquired by Graybug Vision, Inc. on May 10, 2022.
4
| Subsidiary | Biotechnology | 4 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Matthew Hirsch
Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
---|---|---|---|
Liquidia Technologies, Inc.
![]() Liquidia Technologies, Inc. Pharmaceuticals: MajorHealth Technology Liquidia Technologies, Inc. is a clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT technology to transform the lives of patients. It operates in two segments: Pharmaceutical Products and Partnering & Licensing. The two product candidates from its pipeline: LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for the treatment of local post-operative pain. Liquidia Technologies was founded by Joseph M. DeSimone, Ashok K. Mendiratta, Edward T. Samulski, William R. Kenan, Ginger Denison and Jason Rolland in 2004 and is headquartered in Morrisville, NC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
AERIE PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
The University of Chicago | College/University | Masters Business Admin | |
University of California, Irvine | College/University | Doctorate Degree | |
University of California San Diego | College/University | Undergraduate Degree | |
The State University of New York | College/University | Doctorate Degree | |
The North Carolina Biotechnology Center
![]() The North Carolina Biotechnology Center Internet Software/ServicesTechnology Services The North Carolina Biotechnology Center provides research and education grants. Its services include financing, technology assessment, business planning, and marketing strategies implementation. The company was founded in 1984 and is headquartered in Research Triangle Park, NC. | Internet Software/Services | Director/Board Member | |
The Foundation Fighting Blindness, Inc.
![]() The Foundation Fighting Blindness, Inc. Miscellaneous Commercial ServicesCommercial Services The Foundation Fighting Blindness, Inc. provides preventions, treatments and cures for people affected by retinitis pigmentosa, macular degeneration and usher syndrome. The firm also provides provide information on retinal degenerative diseases to all who request it, in order to increase knowledge and awareness of these diseases. It has locations in Columbia, Denver, Libertyville, New York, Plano, Raleigh and Santa Monica. The company was founded on September 16, 1971 and is headquartered in Columbia, MD. | Miscellaneous Commercial Services | Chief Executive Officer | |
CLEARSIDE BIOMEDICAL, INC. | Pharmaceuticals: Major | Director/Board Member | |
Envisia Therapeutics, Inc.
![]() Envisia Therapeutics, Inc. BiotechnologyHealth Technology Envisia Therapeutics, Inc. develops novel ocular therapies. It provides glaucoma drug therapies that include PRINT particle therapeutics to overcome biologic and chemical. The company was founded by 2013 is headquartered in Morrisville, NC. | Biotechnology | Founder | |
GeneTech, Inc.
![]() GeneTech, Inc. Medical/Nursing ServicesHealth Services GeneTech, Inc. engages in fetal deoxyribonucleic acid (DNA) testing and clinical services. The company was founded on October 5, 2010 and is headquartered in Tokyo, Japan. | Medical/Nursing Services | Chief Tech/Sci/R&D Officer | |
Nacuity Pharmaceuticals, Inc.
![]() Nacuity Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Nacuity Pharmaceuticals, Inc. develops and markets pharmaceutical products. The company is headquartered in Fort Worth, TX. | Pharmaceuticals: Major | Director/Board Member | |
SparingVision SAS
![]() SparingVision SAS BiotechnologyHealth Technology SparingVision SAS develops therapeutic approach for treatment of blinding inherited retinal diseases such as retinitis pigmentosa. The company was founded by Jose Alain Sahel, Thierry Leveillard and Florence Allouche Ghrenassia and is headquartered in Paris, France. | Biotechnology | Director/Board Member | |
Tisbury Pharmaceuticals, Inc.
![]() Tisbury Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology Tisbury Pharmaceuticals Ltd. develops and markets groundbreaking therapy to treat primary open angle glaucoma. It focused on the discovery, development, and commercialization of groundbreaking therapy to treat primary open angle glaucoma. The company was founded by Andrew L. Salzman and is headquartered in Beverly, MA. | Medical Specialties | Chief Executive Officer | |
Stargazer Pharmaceuticals, Inc.
![]() Stargazer Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Stargazer Pharmaceuticals, Inc. manufactures pharmaceutical products. The firm engages in the development of treatment for Stargardt’s disease, a rare form of juvenile, retinal degeneration. The company was founded by Gary Jay Sternberg and is headquartered in Boston, MA. | Pharmaceuticals: Major | Founder | |
Retinal Degeneration Fund | Chief Executive Officer | ||
Vedere Bio II, Inc.
![]() Vedere Bio II, Inc. Miscellaneous Commercial ServicesCommercial Services Vedere Bio II, Inc. develops ocular gene therapy. The company is based in Cambridge, MA. The company was founded by Cyrus D. Mozayeni. Cyrus D. Mozayeni has been the CEO since incorporation. | Miscellaneous Commercial Services | Director/Board Member | |
Opus Genetics, Inc.
![]() Opus Genetics, Inc. BiotechnologyHealth Technology Opus Genetics, Inc. is a gene therapy company that focuses on treating inherited retinal diseases. The company is based in Raleigh, NC, and leverages knowledge of the best science and the expertise of pioneers in ocular gene therapy to transparently drive transformative treatments to patients. The company has a unique model and purpose, and is backed by Foundation Fighting Blindness's venture arm, the RD Fund. Opus Genetics has wholly owned programs in numerous orphan retinal diseases, and its AAV-based gene therapy portfolio tackles some of the most neglected forms of inherited blindness while creating novel orphan manufacturing scale and efficiencies. The company was founded in 2021 by Benjamin R. Yerxa, Peter L. Ginsberg, Jason D. Menzo, Jean Bennett, Russell Kelley, Jean Bennett. Benjamin R. Yerxa has been the CEO since 2021. | Biotechnology | Chief Executive Officer |
Statistik
International
Vereinigte Staaten | 19 |
Frankreich | 3 |
Vereinigtes Königreich | 2 |
Japan | 2 |
Sektoral
Health Technology | 13 |
Consumer Services | 5 |
Commercial Services | 3 |
Technology Services | 2 |
Health Services | 2 |
Operativ
Director/Board Member | 9 |
Chief Tech/Sci/R&D Officer | 6 |
Chief Executive Officer | 6 |
President | 4 |
Corporate Officer/Principal | 3 |
Am stärksten vernetzte Beziehungen
Insiders | |
---|---|
Benjamin Yerxa | 15 |
Gary Jay Sternberg | 9 |
Frances Martin | 1 |
Brian Gilger | 1 |
- Börse
- Insiders
- Matthew Hirsch
- Unternehmensverbindungen